Pediatric Interventional Cardiology Market Report 2025

The pediatric interventional cardiology market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased mycotoxin awareness, stringent regulatory standards, focus on animal health, globalization of poultry production, market competitiveness, increased farm productivity.

The pediatric interventional cardiology market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to growing poultry industry, climate change impacts, demand for organic products, global trade dynamics, government initiatives, increasing health consciousness. Major trends in the forecast period include integration of technology, feed quality and safety, market consolidation, collaborative research efforts, digitalization in agriculture, advancements in feed technology.

The pediatric interventional cardiology market is poised for growth due to the increasing prevalence of congenital heart disease, a condition affecting the heart's structure since birth. These procedures offer advantages over traditional open-heart surgery, including quicker recovery, reduced infection risks, and minimized scarring. According to the American Heart Association in 2022, around 40,000 infants in the U.S. are affected by congenital heart defects, with an estimated birth prevalence of 12.3 per 1000 in the country. Additionally, The Lancet reported in 2022 that congenital heart disease is the most common birth defect, impacting nearly 9 out of every 1000 live births. This prevalence is expected to drive the growth of the pediatric interventional cardiology market.

Pedistric population drives the pediatric interventional cardiology market going forward. This demographic refers to individuals within specific age brackets typically associated with childhood and adolescence. According to the Federal Interagency Forum on Child and Family Statistics, the U.S. had around 72.5 million children in 2022, projected to reach 78.2 million by 2050. The rise in this population, spanning different age groups, is expected to fuel the demand for pediatric interventional cardiology procedures.

Product innovation is a significant trend in the pediatric interventional cardiology market. Leading companies in this field are introducing new and creative solutions to enhance their market presence. For example, in February 2023, Medtronic plc., a U.S.-based medical devices company, launched the Harmony Transcatheter Pulmonary Valve System, a transcatheter pulmonary valve. This system serves as a minimally invasive alternative to open-heart surgery and can be implanted through a small incision in the leg or neck. The Harmony TPV system is designed for patients who have previously undergone surgery for congenital heart disease and are experiencing a dysfunctional right ventricular outflow tract (RVOT) due to an earlier implanted conduit or bioprosthetic pulmonary valve. It is also indicated for patients with a native or patched RVOT who need a pulmonary valve replacement.

Major companies in the pediatric interventional cardiology market are prioritizing the development of technological innovations, such as three-dimensional transesophageal echocardiography (3D TEE), to secure a competitive advantage. In pediatric interventional cardiology, real-time 3D TEE provides intricate images of congenital heart defects, including atrial and ventricular septal defects, which are vital for planning and guiding minimally invasive procedures. For example, in January 2024, Philips, a healthcare technology company based in the Netherlands, launched the X11-4T Mini 3D TEE transducer. This state-of-the-art transducer enhances three-dimensional transesophageal echocardiography (TEE) by delivering detailed imaging essential for diagnosing congenital heart defects in children. Notable features include its compact design, which improves maneuverability in pediatric patients, high-resolution imaging capabilities that boost diagnostic accuracy, and compatibility with existing echocardiography systems for a seamless workflow. These advancements substantially enhance procedural outcomes and patient care within pediatric cardiology.

In February 2022, Boston Scientific Corporation, a prominent U.S. biomedical and biotechnology firm, completed the acquisition of Baylis Medical Company Inc. for an estimated $1.75 billion. This strategic move is aimed at fortifying Boston Scientific Corporation's standing within the cardiology markets, specifically by enhancing its offerings in advanced solutions for catheter-based left-heart procedures. Baylis Medical Company Inc., also based in the U.S., specializes in cutting-edge medical devices operating within high-technology cardiology, endovascular, and oncology realms.

Major companies operating in the pediatric interventional cardiology market include Medtronic plc, GE HealthCare Technologies Inc., Abbott Laboratories, Terumo Corporation, W.L. Gore & Associates Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Siemens Healthineers, Numed Inc., St. Jude Medical Inc., Cordis Corporation, Koninklijke Philips N.V., Biotronik, B. Braun Melsungen AG, Canon Medical Systems Corporation, Gore & Associates Inc., Johnson and Johnson, Cook Group LLC, Teleflex Incorporated, Merit Medical Systems Inc., MicroPort Scientific Corporation, Lepu Medical Technology (Beijing) Co.Ltd., Biosensors International Group Ltd., Cardiac Science Corporation, Asahi Intecc Co.Ltd., Medinol Ltd., Jotec GmbH, Hexacath Ltd., Translumina GmbH.

North America was the largest region in the pediatric interventional cardiology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global pediatric interventional cardiology market during the forecast period. The regions covered in the pediatric interventional cardiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric interventional cardiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pediatric interventional cardiology involves utilizing cardiac catheterization in children to both diagnose and treat congenital heart defects through minimally invasive procedures. These procedures aim to address various heart conditions while minimizing surgical invasiveness.

Key devices within pediatric interventional cardiology encompass closure devices, trans catheter heart valves, atherectomy devices, catheters, balloons, stents, among others. Closure devices encompass a range of fittings that, when securely fastened in a closed position, mitigate or prevent air emissions by sealing openings in containers or their exteriors. The primary procedures in pediatric interventional cardiology involve catheter-based valve implantation, correction of congenital heart defects, angioplasty, coronary thrombectomy, and other methodologies. These procedures find application in clinical testing labs, hospitals, cardiac centers, pediatric clinics, and research institutions, contributing significantly to diagnosing and managing cardiac conditions in children.

The pediatric interventional cardiology market research report is one of a series of new reports that provides pediatric interventional cardiology market statistics, including pediatric interventional cardiology industry global market size, regional shares, competitors with a pediatric interventional cardiology market share, detailed pediatric interventional cardiology market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric interventional cardiology industry. This pediatric interventional cardiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pediatric interventional cardiology market includes revenues earned by entities by percutaneous coronary intervention services, atrial septal defect services, cardiac catheterization services, and trans catheter aortic valve replacement services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The pediatric interventional cardiology market also consists of sales of plaque modification devices, guide wire, vascular closure devices, and atherectomy device. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.